This workbook consists of introductory reading and five distinct modules that encourage you to reflect on your CVD risk assessment and management practices, risk communication, cultural safety, and your engagement with young adult Māori and Pacific patients.
The current primary care CVD management guidance strongly recommends aggressive risk management and lifestyle modification in patients with pre-existing CVD or an equivalent CVD risk. Significant opportunities to improve use of CVD medicines remain, particularly for Māori and Pacific peoples who lose 2.6–2.8 times more years to CVD events relative to non-Māori/non-Pacific peoples.
In this article, Dr Jim Vause contemplates managing CVD risk, reasons for non-adherence, inequities in CVD treatment, and how to improve communication with patients.
Rosuvastatin is now fully funded on Special Authority for people at increased risk of cardiovascular complications due to high cholesterol, and may be considered first-line for Māori and Pacific peoples.
An abridged version of this article, containing the eligibility flowchart, is available for printing - see the link in the contents box.
In this webinar, Dr Raewyn Fisher discusses the range of disease-modifying therapies that have improved heart failure outcomes, and provides reassurance around the funding changes to cilazapril.
Last year, cilazapril with hydrochlorothiazide was discontinued, and now cilazapril alone is no longer funded for new patients. Consultant cardiologist Chris Ellis discusses what to do when patients with hypertension run out of their supply of these medications
Prescribers wanting to block angiotensin II effects can consider the remaining funded ACE inhibitors or angiotensin II receptor blockers. ACE inhibitors and ARBs are similarly effective for hypertension, chronic renal disease and diabetic nephropathy, but ARBs are better tolerated.2 ACE inhibitors are preferred over ARBs first-line for heart failure and post myocardial infarction.2
Read the HAH Bulletin to find out more.